142 related articles for article (PubMed ID: 16462684)
1. [Transversal study of the psychosocial rehabilitation and the quality of life of 75 schizophrenics under classical neuroleptics or atypical antipsychotic neuroleptics].
Guillard-Bouhet N; Lafay N; Jourdain M; Senon JL
Encephale; 2005; 31(6 Pt 1):653-65. PubMed ID: 16462684
[TBL] [Abstract][Full Text] [Related]
2. [Comparative evaluation of quality of life in patients with schizophrenia treated with conventional versus atypical neuroleptics: results of a transversal study].
Divanon F; Delamillieure P; Lehaguez A; Vasse T; Morello R; Gourevitch R; Langlois S; Assouly-Besse F; Guelfi JD; Petit M; Dollfus S
Encephale; 2006; 32(4 Pt 1):459-65. PubMed ID: 17099557
[TBL] [Abstract][Full Text] [Related]
3. [Quality of life of patient with schizophrenia treated by conventional and atypical neuroleptics].
Zaghdoudi L; Homri W; Belaid S; Ben Bechir M; Labbane R
Tunis Med; 2009 Sep; 87(9):593-8. PubMed ID: 20180380
[TBL] [Abstract][Full Text] [Related]
4. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
5. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic benefit of a registered psychoeducation program on treatment adherence, objective and subjective quality of life: French pilot study for schizophrenia].
Sauvanaud F; Kebir O; Vlasie M; Doste V; Amado I; Krebs MO
Encephale; 2017 May; 43(3):235-240. PubMed ID: 27658989
[TBL] [Abstract][Full Text] [Related]
7. [Adverse effects of antipsychotics and quality of life].
Mínguez Martín L; González Pablos E; Alonso del Teso F; Sanguino Andrés RM; García Alonso Y
Actas Esp Psiquiatr; 2005; 33(1):1-6. PubMed ID: 15704024
[TBL] [Abstract][Full Text] [Related]
8. Short-term cognitive improvement in schizophrenics treated with typical and atypical neuroleptics.
Rollnik JD; Borsutzky M; Huber TJ; Mogk H; Seifert J; Emrich HM; Schneider U
Neuropsychobiology; 2002; 45(2):74-80. PubMed ID: 11893863
[TBL] [Abstract][Full Text] [Related]
9. [The subjective quality of life of patients with schizophrenia: influence of psychopathology and patients' expectations. A comparative study].
Salomé F; Petitjean F; Germain C; Demant JC
Encephale; 2004; 30(1):60-8. PubMed ID: 15029078
[TBL] [Abstract][Full Text] [Related]
10. [Quality of life in schizophrenic patients treated with classic and "old" atypical neuroleptics].
Jarema M; Konieczyńska Z
Psychiatr Pol; 2000; 34(2):275-88. PubMed ID: 10974941
[TBL] [Abstract][Full Text] [Related]
11. The role of neuroleptics in an integrated treatment program for chronic schizophrenics.
Gottfries I; Rüdeberg K
Acta Psychiatr Scand Suppl; 1981; 291():44-55. PubMed ID: 6113734
[TBL] [Abstract][Full Text] [Related]
12. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics.
Juckel G; Schlagenhauf F; Koslowski M; Filonov D; Wüstenberg T; Villringer A; Knutson B; Kienast T; Gallinat J; Wrase J; Heinz A
Psychopharmacology (Berl); 2006 Aug; 187(2):222-8. PubMed ID: 16721614
[TBL] [Abstract][Full Text] [Related]
13. [Benzodiazepines and schizophrenia, a review of the literature].
Gaillard R; Ouanas A; Spadone C; Llorca PM; Lôo H; Baylé FJ
Encephale; 2006; 32(6 Pt 1):1003-10. PubMed ID: 17372546
[TBL] [Abstract][Full Text] [Related]
14. Implicit and explicit learning in schizophrenics treated with olanzapine and with classic neuroleptics.
Stevens A; Schwarz J; Schwarz B; Ruf I; Kolter T; Czekalla J
Psychopharmacology (Berl); 2002 Mar; 160(3):299-306. PubMed ID: 11889499
[TBL] [Abstract][Full Text] [Related]
15. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients.
Franz M; Lis S; Plüddemann K; Gallhofer B
Br J Psychiatry; 1997 May; 170():422-5. PubMed ID: 9307690
[TBL] [Abstract][Full Text] [Related]
16. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment.
Hunter R; Barry S
Eur Psychiatry; 2012 Aug; 27(6):432-6. PubMed ID: 21602034
[TBL] [Abstract][Full Text] [Related]
17. Subjective well-being and quality of life under atypical antipsychotic treatment.
Karow A; Naber D
Psychopharmacology (Berl); 2002 Jun; 162(1):3-10. PubMed ID: 12107610
[TBL] [Abstract][Full Text] [Related]
18. [Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia].
Brunot A; Lachaux B; Sontag H; Casadebaig F; Philippe A; Rouillon F; Cléry-Melin P; Hergueta T; Llorca PM; Moreaudefarges T; Guillon P; Lebrun T
Encephale; 2002; 28(2):129-38. PubMed ID: 11972139
[TBL] [Abstract][Full Text] [Related]
19. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
20. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
Awad AG; Voruganti LN
CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
